| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Biomedical Sciences, Creighton University, Omaha, Nebraska, United States
2 Research Service, Department of Veterans Affairs - Nebraska Western Iowa Health Care System, Omaha, Nebraska, United States
3 Biomedical Sciences, Creighton University, Omaha, Nebraska, United States; Research Service, Department of Veterans Affairs - Nebraska Western Iowa Health Care System, Omaha, Nebraska, United States
* To whom correspondence should be addressed. E-mail: roger.reidelberger{at}va.gov.
Peptide YY(3-36) [PYY(3-36)] is a gut-brain peptide that decreases food intake when administered by intravenous infusion to lean and obese humans, and rats. Yet, chronic administration of PYY(3-36) by osmotic minipump to lean and obese rodents produces only a transient reduction in daily food intake and weight gain. We recently showed that 1-hour intravenous infusions of PYY(3-36) every other hour for 10 days produced a sustained reduction in daily food intake, body weight and adiposity in lean rats. Here we determined whether intermittent delivery of PYY(3-36) can produce a similar response in diet-induced obese rats. During a 21-day period, obese rats (body fat>25%) received twice daily intraperitoneal infusion of vehicle (n=18) or PYY(3-36) (n=24) during hours 1-3 and 7-9 of the dark period. Rats had free access to both a 45%-fat solid diet and a 29%-fat liquid diet; intakes were determined from computer recording of changes in food container weights. In order to sustain a 15-25% reduction in daily caloric intake, the initial PYY(3-36) dose of 30 pmol/kg/min was reduced to 10 pmol/kg/min on day 10, and then increased to 17 pmol/kg/min on day 13. This dosing strategy produced a sustained reduction in daily caloric intake of 11-32%, and prevented body weight gain (8 ± 6 g vs. 51 ± 11g) and fat deposition (4.4 ± 7.6 g vs. 41.0 ± 12.8 g). These results indicate that intermittent intraperitoneal infusion of PYY(3-36) can produce a sustained reduction in food intake and adiposity in diet-induced obese rodents consuming palatable high-fat foods.
This article has been cited by other articles:
|
|
 |
|
  N. Yang, X. Liu, E. L. Ding, M. Xu, S. Wu, L. Liu, X. Sun, and F. B. Hu Impaired Ghrelin Response after High-Fat Meals Is Associated with Decreased Satiety in Obese and Lean Chinese Young Adults J. Nutr., July 1, 2009; 139(7): 1286 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Karra, K. Chandarana, and R. L. Batterham The role of peptide YY in appetite regulation and obesity J. Physiol., January 1, 2009; 587(1): 19 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Maier, M. Riedl, G. Vila, P. Nowotny, M. Wolzt, M. Clodi, B. Ludvik, and A. Luger Cholinergic Regulation of Ghrelin and Peptide YY Release May Be Impaired in Obesity Diabetes, September 1, 2008; 57(9): 2332 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Reidelberger, A. C. Haver, P. K. Chelikani, and J. L. Buescher Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R449 - R458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1798 - R1808. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
